Hyloris Pharmaceuticals SA (EBR: HYL)

Market Cap	148.40M
Revenue (ttm)	6.94M
Net Income (ttm)	-13.24M
Shares Out	28.00M
EPS (ttm)	-0.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,692
Open	5.60
Previous Close	5.54
Day's Range	5.26 - 5.60
52-Week Range	2.89 - 13.30
Beta	0.45
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 20, 2025

About Hyloris Pharmaceuticals

Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 41
• Stock Exchange: Euronext Brussels
• Ticker Symbol: HYL

Financial Performance

In 2023, Hyloris Pharmaceuticals's revenue was 4.21 million, an increase of 76.54% compared to the previous year's 2.39 million. Losses were -15.38 million, 29.2% more than in 2022.